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Abstract
Background: RAD51D (RAD51 paralog D) is an intermediate cancer susceptibility gene for primary ovarian cancer,
including fallopian tube and peritoneal carcinomas and breast cancer. Although gynecological non-epithelial
tumors such as uterine sarcomas are associated with genomic instability, including BRCA impairment, there is no
clear evidence of the relationship between RAD51D variants and the risk of sarcoma development.
Case presentation: A Japanese woman in her 50s underwent multiple surgical resections and several regimens of
chemotherapy for tumors that originated in the retroperitoneum and recurred in the peritoneum over a clinical
course of approximately 4 years. The peritoneal tumor was histologically diagnosed as a leiomyosarcoma and was
genetically identified to show a splice variant of RAD51D c.904-2A > T [NM_002878] through tumor profiling
performed as a part of cancer precision medicine. The confirmatory genetic test performed after genetic counseling
revealed that the RAD51D splicing variant detected in her tumor was of germline origin. In silico analyses supported
the possible pathogenicity of the detected splice variant of RAD51D with a predicted attenuation in mRNA
transcription and truncated protein production due to frameshifting, which was attributed to a single-nucleotide
alteration in the splicing acceptor site at the 3′-end of intron 9 of RAD51D. Considering her unfavorable clinical
outcome, which showed a highly aggressive phenotype of leiomyosarcoma with altered RAD51D, this case
provided novel evidence for the relationship of a RAD51D splicing variant with malignant tumor development or
progression. We report the findings of this rare case with possible involvement of the germline variant of RAD51D
c.904-2A > T as a potential predisposing factor for malignant tumors, including leiomyosarcoma.
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Conclusions: We present the findings of a case of leiomyosarcoma in the peritoneum of a female patient with a
novel germline splicing variant of RAD51D as potential evidence for the pathogenicity of the variant and its
involvement in the risk of sarcoma etiology and/or development. To the best of our knowledge, this is the first case
report describing a leiomyosarcoma carrying a germline RAD51D splicing variant and elucidating its pathogenicity
on the basis of computational prediction of the impairment of normal transcription and the presumed loss of
functional protein production.
Keywords: RAD51D, Splice variant, Leiomyosarcoma, Homologous recombination (HR), Cancer susceptibility,
Presumed germline pathogenic variant (PGPV)
Background
The RAD51 paralog D (RAD51D) is one of five RAD51
paralog members, namely, RAD51B (RAD51L1),
RAD51C (RAD51L2), RAD51D (RAD51L3), XRCC2,
and XRCC3. These members assist in the recruitment of
RAD51, which functions as a DNA recombinase during
DNA replication and plays crucial roles in DNA double-
strand break (DSB) repair by homologous recombination
(HR) on damaged DNA [1, 2]. RAD51D forms a sub-
complex with RAD51B, RAD51C, and XRCC2 (BCDX2
complex), which is regulated by the BRCA1-PALB2-
BRCA2 effector complex upstream of RAD51 [3, 4]. Ac-
cumulating evidence over the recent years indicates that
the inherited inactivation of these HR-associated genes
is correlated with a predisposition to female malignan-
cies with various risks and penetrance rates [5]. For in-
stance, RAD51C germline variants have been
demonstrated to be susceptibility factors for both ovar-
ian and breast cancers. Germline variants of RAD51D,
most of which are truncated, were principally shown in
ovarian cancer with an estimated six-fold increase in risk
[6, 7]. Several studies performed in Western and Eastern
countries showed evidence of moderate penetrance of
ovarian cancer by germline RAD51D variants, regardless
of ethnicity [8–10]. In a population-based cohort and a
screening trial of individuals at high risk of ovarian can-
cer, both RAD51C and RAD51D were shown to be mod-
erately susceptible to ovarian cancer, suggesting the
usefulness of these genes alongside BRCA1/2 for the
prediction of susceptibility to ovarian cancer [11]. Ac-
cording to another large segregation analysis, the cumu-
lative risks of tubo-ovarian cancer up to the age of 80
years were estimated to be 11 to 13% for RAD51D and
RAD51C variant carriers, respectively [12]. Other epi-
demiological studies have reported associations between
RAD51D germline variants and breast cancer risk re-
gardless of the subtype of breast cancer [12, 13]. One
study also suggested a potential therapeutic strategy tar-
geting HR-related genes, which show alterations in sar-
comas arising from gynecologic organs [14]. The
benefits of using poly (ADP-ribose) polymerase (PARP)
inhibitors to overcome the very poor prognosis of gyne-
cologic sarcoma have also been shown in a recent study
[15]. As further novel evidence, in this case report, we
demonstrate a rare peritoneal leiomyosarcoma with a
germline background of RAD51D c.904-2A > T [NM_
002878], a splicing variant of RAD51D, that can be inter-
preted as pathogenic based on its aggressive clinical
phenotype in the present case and through computational
predictions for attenuated transcription and translation of
the gene. We also present a case in which the RAD51D
variant was identified as a presumed germline pathogenic
variant (PGPV) in cancer precision medicine and was suc-
cessfully referred for genetic counseling including the pa-
tient’s family members in a timely manner.
Case presentation
A Japanese woman in her 50s underwent surgical resection
for a tumor arising in the left retroperitoneum. Preoperative
computed tomography (CT) and positron emission tomog-
raphy (PET)-CT as well as intraoperative findings showed no
distant metastasis, no obvious peritoneal dissemination, and
no invasion of the uterus or ovaries (Supplementary Infor-
mation). Histologically, the tumor was identified as a leio-
myosarcoma of 12 cm× 11 cmin size. She was treated with
postoperative chemotherapy with 6 cycles of doxorubicin,
followed by chemotherapy with pazopanib for 8months.
During the observational follow-up period, imaging studies
indicated peritoneal recurrence. While chemotherapy with
pazopanib was promptly restarted, the tumor mass eventu-
ally grew to an obvious tumor in the peritoneum. She under-
went debulking surgery twice for peritoneal tumors, but the
tumors recurred. She received chemotherapy with gemcita-
bine and docetaxel, which was discontinued due to the onset
of interstitial pneumonia. Cancer genome profiling was con-
ducted to search for genome-matched treatment strategies
in daily clinical practice in cancer precision medicine. She
was referred to us for genetic counseling and interpretation
of the RAD51D splicing variant, which was originally de-
tected in the tumor genome profiling analysis. She had no
family history of RAD51-related cancers or other types of
malignancies, including sarcoma (Fig. 1).
In histological assessments, the tumor showed fascicu-
lar proliferation of spindle cells with eosinophilic cyto-
plasm. The nuclei showed moderate atypia, and some
tumor cells had prominent nucleoli. Occasional mitotic
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figures were also observed. Tumor necrosis was not ob-
served (Fig. 2a). In immunohistochemical studies per-
formed at Mita Hospital adjunctive to the International
University of Health and Welfare, Japan, the tumor cells
were shown to be weakly positive for α-smooth muscle
actin and desmin. These findings are consistent with a
diagnosis of leiomyosarcoma, equivalent to histological
grade 1 according to the French Federation of Cancer
Centers Sarcoma Group (FNCLCC) grading system for
sarcoma [16].
Through genomic profiling analysis of the desig-
nated 324 genes of the patient’s tumor samples by
using the FoundationOne CDx® (Foundation Medi-
cine Inc., MA, USA) oncology panel, two pathogenic
variants in RAD51D (splicing variant) and TP53
(missense variant) and intermediate amplifications of
four genes were detected (Table 1). On the basis of
the recommendations by the expert panel, which is a
tumor board that provides molecular and clinical in-
terpretations and suggestions for the results of on-
cology panel testing, the patient received genetic
counseling and subsequently underwent germline
analysis for RAD51D c.904-2A > T [NM_002878].
The same splicing variant of RAD51D was detected
in the analysis of DNA extracted from lymphocytes
by direct DNA sequencing using capillary gel elec-
trophoresis and fluorescence detection (Sanger se-
quencing technique and application), which was
performed in a Clinical Laboratory Improvement
Amendments (CLIA)-certified laboratory. After ex-
tensive genetic counseling based on the results ob-
tained from germline testing, her two daughters,
shown as IV-1 and IV-2, also underwent predictive
genetic testing, and both were found to be positive
for the variant (Fig. 1).
In silico prediction and clinical interpretation of RAD51D
c.904-2A > T [NM_002878]
To evaluate the potential effects of the spicing variant
due to a single-nucleotide alteration at the 3′-end of in-
tron 9, the schematic structure and location of which
are shown in Fig. 2b, we used four computational pre-
diction tools, Max Entropy Scan (MES), NetGene2,
Splice Site Prediction by Neural Network (NNSplice),
and Alternative Splice Site Predictor (ASSP) to analyze
the potential effects of RAD51D c.904-2A > T [NM_
002878]. All four tools predicted that the RAD51D vari-
ant attenuated normal splicing and yielded a shorter
form of the RAD51D protein (Table 2 and Supplemen-
tary Information). Furthermore, cBROCA analysis, an
experimental analysis for RNA as shown by Casadei
et al. [17], also predicted that this alteration would
weaken the native splice acceptor site and create or
strengthen alternative novel splice acceptor sites, result-
ing in shorter forms of the protein products of RAD51D.
Taken together, these computational analyses suggest
that a single-nucleotide alteration in intron 9 of
RAD51D c.904-2A > T [NM_002878] attenuates normal
splicing of RAD51D mRNA, resulting in the production
of a shorter form of RAD51D protein (a representative
truncated product is shown in Fig. 2c and d). Although
there are no specific consensus domains in exon 10,
which is truncated by attenuated splicing, the aggres-
sively malignant phenotypes observed in this case would
be evidence for RAD51D c.904-2A > T [NM_002878] as
a novel loss-of-function variant involved in the forma-
tion and/or progression of malignant tumors.
According to the ClinVar database (Variation ID:
472631) (https://www.ncbi.nlm.nih.gov/clinvar/, accessed
in August 2021), the clinical significance of RAD51D
c.904-2A > T [NM_002878] is likely pathogenic or un-
certain, meaning that its clinical significance has not yet
been determined and is a subject of debate in interpret-
ation. Allele frequencies of RAD51D c.904-2A > T (NM_
002878) in the general population were 6.60 × 10− 4
(ToMMo 8.3KJPN) and 4.13 × 10− 4 (HGVD ver2.3,
dbSNP rsID: 1403784434) in Japanese people and 3.98 ×
10− 6 in the global population, suggesting that the spli-
cing variant RAD51D c.904-2A > T [NM_002878] was
extremely rare in the global population as well as in
Japan, which may be potentially indicate that it is a
pathogenic variant (Table 3).
Discussion
We report a case presenting with a high implication of
pathogenicity for the splicing variant RAD51D c.904-
2A > T [NM_002878], which was identified through can-
cer precision medicine in a female patient with retro-
peritoneal leiomyosarcoma and confirmed to be of
germline origin in the patient involved. According to the
Fig. 1 The patient’s family pedigree. The arrow shows the proband
(III-1) with leiomyosarcoma. The black circle indicates an individual
with cancer. Other symptoms are indicated by unfilled circles or
squares. E+ signs (III-1, IV-1 and VI-2) represent a positive evaluation
for the indicated variant of RAD51D by genetic testing
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Fig. 2 a Histological findings of the tumor specimen. Two representative high-magnification views of hematoxylin and eosin-stained specimens
are shown. Scale bars = 50 μm. b Schematic structure of RAD51D. Consensus regions/domains such as linker region and ATPase domain are
shown in black or oblique-lined boxes. The number of amino acids (aa 1–328) is displayed on the top of the box. Amino acid numbers for each
region/domain were obtained from a previous study by Chen et al. [13]. The number of exons (exons 1–10) translated to proteins are described
below the box. The locus of RAD51D c.904-2A > T is in the carboxyl terminal of intron 9. Nucleotide numbering was based on the National
Cancer for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov) reference sequence NM_002878. c DNA sequences of wild-type (WT)
RAD51D and the splice variant of RAD51D c.904-2A > T (Mut) with a plausible splicing acceptor site in the original exon 10 of RAD51D. AGs in gray
boxes are splice acceptor sites of WT and an alternative splice site of Mut, respectively. TGA or TAG, outlined in black boxes, are termination
codons. We suspect that a new splicing junction appeared 7 bp downstream from the 5′-end of exon 10, which resulted in the production of an
aberrant mRNA. d Protein structure of WT (328 aa) and a representative variant of Mut (306 aa). The 7-base deletion of exon 10 (c.904_910del)
causes a translational frameshift and produces a premature stop codon at six amino acids downstream from the 302nd of valine (abbreviated as
V), as shown with an arrow. (p.P302Vfs*6). aa, amino acids; Ter, termination codon (stop codon)
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epidemiological databases of the Genome Aggregation
Database (gnomAD) ver 2.1.1 and Trans-Omics for Pre-
cision Medicine (TOPMed), the frequencies of RAD51D
c.904-2A > T [NM_002878] carriers in the general popu-
lation worldwide are as rare as 3.98 × 10− 6 and 4.00 ×
10− 6, respectively (Table 3). Although the frequencies
increased up to 6.60 × 10− 4 (ToMMo 8.3KJPN) or
4.13 × 10− 4 (HGVD ver2.3) in the general cohorts in
Japan, all of them were less than 1 × 10− 3 (0.1%), making
the variant rare enough to be interpreted as pathogenic,
since rarity is a prerequisite factor for the interpretation
of clinical pathogenicity of variants according to the
practical criteria in clinical genetics [18].
In the previous literature, germline RAD51D c.904-
2A > T [NM_002878] was reported in a few cases of car-
cinoma, such as ovarian serous carcinoma, cholangiocar-
cinoma of the bile duct, and breast carcinoma [19–21]
(Table 4). Considering the unfavorable clinical outcomes
observed in this patient carrying a germline variant of
RAD51D, this case provides evidence for the potential
pathogenicity of RAD51D c.904-2A > T [NM_002878],
indicating its susceptibility to a wide range of malignan-
cies. This case shows leiomyosarcoma not only as an-
other related malignancy but also a rare case, which is
so-called “off-tumor” [22], in the presence of a germline
variant of RAD51D.
According to the standards and guidelines for the in-
terpretation of variants recommended by the American
College of Medical Genetics and Genomics (ACMG)
and the Association for Molecular Pathology (AMP), the
presence of intronic variants with loci within ±2 bases
from the 5′- or 3′-end of splice sites, as seen in this
case, can be rationally interpreted as evidence for patho-
genicity because the variants in splicing acceptor sites
typically lead to loss of function due to impaired splicing
[23]. In silico analyses predicted that RAD51D c.904-
2A > T [NM_002878] would affect the splice acceptor
site of intron 9 and result in frameshifting and attenu-
ated mRNA transcription, with premature stop codons
localized in the middle of exon 10 (Fig. 2c and 2d). Ana-
lyses using four computational prediction tools sup-
ported the higher potential of RAD51D c.904-2A > T
[NM_002878] than the wild type in the aberrant splicing
of RAD51D (Table 2).
Although the histological diagnosis for this case using
the resected tissue was clearly leiomyosarcoma, there
were some tricky points that could otherwise be con-
fused with primary or recurrent peritoneal carcinoma
due to the location (peritoneum) and the gene in which
the variant was detected (RAD51D). Since RAD51D is
frequently associated with epithelial carcinoma but not
with non-epithelial sarcoma, this case provides novel evi-
dence for the crucial role of the RAD51D splicing variant
in risk elevation for malignancies, including non-
epithelial tumors. Another point to be considered in this
case was the presence of a variant of TP53 that was
identified in the tumor sequencing (Table 1). Wild-type
TP53 can suppress RAD51 transcription by binding to
the RAD51 promoter [24]. RAD51 is overexpressed in
many tumors as a complementary mechanism against
defects in DNA damage repair, including impaired HR
by BRCA1 and BRCA2 [25]. In addition, TP53 variants
are commonly found in leiomyosarcoma, for example, as
many as 50% of sporadic leiomyosarcomas are known to
show TP53 variants [26]. In contrast, the clinical signifi-
cance of the missense variant of TP53 (TP53 T155I)
Table 1 List of genes showing alterations in the tumor-only
sequence
Genes Alteration CN VAF (%)
RAD51D Splice site 904-2A>T N/A 50.99
TP53 T155I N/A 86.63
AURKB Amplification 10 N/A
C17orf39 (GID4) Amplification 9 N/A
EGFR Amplification 7 N/A
IGF1R Amplification 8 N/A
CN copy number, VAF Variant allele fraction, N/A, not applicable (N/A)
Table 2 In silico predictions for the splicing of RAD51D wild-
type (WT) and c.904-2A>T [NM_002878] (c.904-2A>T)
WT c.904-2A>T (Mut)
Tools (A) (B) (A) (B)
MES 100 29.4 -2.45 137.1
NetGene2 100 163.6 0 165.3
NNSplice 100 - - 101.1
ASSP 100 67.5 - 89.6
Potential effects on splicing at the original site (A) or an alternative site in
exon 10 (B) predicted by each tool are shown as fold-increase of the
prediction score. Raw scores and methods of prediction analysis by each tool
and schemas are available in the Supplementary Information
MES Max Entropy Scan, NNSplice Splice Site Prediction by Neural Network,
ASSP Alternative Splice Site Predictor
Table 3 Allele frequencies of RAD51D c.904-2A>T [NM_002878]
in general population groups
Database Population Allele number Allele frequency
HGVD Japanese 2,420 4.13 × 10-4
GEM-J WGA Japanese 15,162 6.60 × 10-4
ToMMo Japanese 16,760 6.60 × 10-4
KRGDB Korean 2,922 3.00 × 10-4
gnomAD East Asian 18,394 5.44 × 10-5
gnomAD Global 251,488 3.98 × 10-6
TOPMed Global 264,690 4.00 × 10-6
Allele frequency is the fraction with germline variants of RAD51D c.904-2A>T
among the general population according to each database. Allele number is
the total number of allele which was analyzed in each database. All data were
obtained by accessing each database in August 2021. Web sites for reference
are shown in the Supplementary Information
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found in tumors in this case is uncertain according to
the ClinVar database (Variation ID: 1005876) and neu-
tral in the FATHMM prediction under the COSMIC
database (Genomic Mutation ID: COSV52741190) with
a score below 0.5 (0.39), suggesting that the TP53 vari-
ant found in this case would be a wild-type-ish variant
that would lead to suppression of RAD51 expression due
to the regulation mechanism of RAD51 by TP53. Over-
all, in this case, the non-compensated steady level of
RAD51 plus abnormal RAD51D protein production due
to its splicing variant might have transformed the tissue
phenotypes into a highly aggressive type of sarcoma.
Nevertheless, considering the hypothetical nature of
these assumptions, they should be analyzed in greater
detail in further investigations.
Regarding the family members in this case, two daugh-
ters successfully received genetic counseling. The same
splicing variant of RAD51D was detected in both of
them as a germline background (Fig. 1). Their referral to
genetic counseling at a proper time point enabled them
to start their risk management and clinical surveillance
for ovarian cancer, including peritoneal tumor, breast
cancer, and even sarcomas. This case is also a good ex-
ample in which a presumed germline origin variant was
found through tumor-only profiling analysis and con-
firmed by germline testing in a timely manner, even in
family members. The clinical surveillance of the family
members will provide valuable evidence that will con-
tribute to conclusive determination of the clinical signifi-
cance of RAD51D c.904-2A > T [NM_002878]. By
considering an ongoing clinical trial using poly (ADP-ri-
bose) polymerase (PARP) inhibitors on leiomyosarcoma,
HR-related genes, including the RAD51D splicing variant
identified in this case, can be a good clinical molecular
marker not only for risk prediction but also for the
choice of treatments for leiomyosarcoma.
In conclusion, we present a case of recurrent leiomyo-
sarcoma in the peritoneum that showed evidence of a
germline background for the RAD51D splicing variant in
intron 9 implies the clinical risk elevation for malignant
tumors, including sarcomas. To the best of our know-
ledge, this is the first case report of leiomyosarcoma
other than carcinomas with a germline background of
RAD51D c.904-2A > T [NM_002878].
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